CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA Inc.

1:25-cv-00018

Overview

Case Number 1:25-cv-00018
Filing Date 2025-01-06
Status Litigation filed
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Hikma Pharmaceuticals PLC NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Hikma Pharmaceuticals USA Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Nexus Pharmaceuticals, LLC Operating Company

Represented By

2 Attorneys Listed

Christine Dealy Haynes

Richards, Layton & Finger

Tel: +1 (302) 651-7508

Richards, Layton & Finger, 920 North King Street

Kelly E. Farnan

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7705

Richards, Layton & Finger, PA, One Rodney Square

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US11464752
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Filed: 2021-07-21
Issued: 2022-10-11
Active (14.7 yrs remaining)
Expires: 2041-07-21
US11426369
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Filed: 2021-12-20
Issued: 2022-08-30
Active (15.1 yrs remaining)
Expires: 2041-12-20
US11571398
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Filed: 2022-09-12
Issued: 2023-02-07
Active (15.8 yrs remaining)
Expires: 2042-09-12

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

0

Granted

0

Denied

0

Pending / Review

5

Motions by Category

Procedural / Extension Motion 5

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Stipulation-General (See Motion List for Stipulation to Extend Time)
Entry #34 • 2025-12-04 Document →
Procedural / Extension Motion Pending / Under Review
Stipulation-General (See Motion List for Stipulation to Extend Time)
Entry #33 • 2025-11-06 Document →
Procedural / Extension Motion Pending / Under Review
Stipulation to EXTEND Time
Entry #26 • 2025-09-25 Document →
Procedural / Extension Motion Pending / Under Review
Stipulation-General (See Motion List for Stipulation to Extend Time)
Entry #22 • 2025-08-29 Document →
Procedural / Extension Motion Pending / Under Review
Stipulation to EXTEND Time
Entry #9 • 2025-01-30 Document →

Docket Entries

(54 total)
Pleading / Complaint

COMPLAINT with Jury Demand against Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals USA Inc. (Filing fee $ 405, receipt number ADEDC-4583298) - filed by Nexus Pharmaceuticals, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(oam) (Entered: 01/07/2025)

Entry #1 • 2025-01-06
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) (Entered: 01/07/2025)

Entry #2 • 2025-01-06
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,464,752 B2; 11,426,369 B2; 11,571,398 B1. (oam) (Entered: 01/07/2025)

Entry #3 • 2025-01-06
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Nexus Family Holdings, Inc. for Nexus Pharmaceuticals, LLC filed by Nexus Pharmaceuticals, LLC. (oam) (Entered: 01/07/2025)

Entry #4 • 2025-01-06
1

Summons Issued as to Hikma Pharmaceuticals PLC on 1/6/2025; Hikma Pharmaceuticals USA Inc. on 1/6/2025. (Attachments: # 1 Summons Issued)(oam) (Entered: 01/07/2025)

Entry #5 • 2025-01-06
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc